Engineering of a novel adjuvant based on lipid-polymer hybrid nanoparticles: A quality-by-design approach

Rose, Fabrice; Wern, Jeanette Erbo; Ingvarsson, Pall Thor; Weert, Marco van de; Andersen, Peter; Follmann, Frank

doi:10.1016/j.jconrel.2015.05.004

Cited by 85 publications

(38 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Liposome-based microneedle array (LiposoMAs) and a mannose-PEG-cholesterol (MPC)/lipid A-liposome (MLLs) system are both examples of liposome formulations with a balanced Th1/Th2 response [109–111]. An even more complex vector is the combination of nanoparticle technology and liposomes with biodegradable poly(DL-lactic-co-glycolic acid) (PLGA), cationic surfactant dimethyldioctadecylammonium (DDA) bromide, and the immunopotentiator TDB which promotes Th1 and Th17 CD4 + T cell responses and enhanced specific serum antibodies [112]. Moreover, the mycobacterial cell-wall lipid monomycoloyl glycerol analog has been used in combination with DDA.…”

Section: Mucosal Immune Responses To Liposomesmentioning

confidence: 99%

Mucosal Vaccine Development Based on Liposome Technology

Bernasconi

Norling

Bally

et al. 2016

Journal of Immunology Research

View full text Add to dashboard Cite

Immune protection against infectious diseases is most effective if located at the portal of entry of the pathogen. Hence, there is an increasing demand for vaccine formulations that can induce strong protective immunity following oral, respiratory, or genital tract administration. At present, only few mucosal vaccines are found on the market, but recent technological advancements and a better understanding of the principles that govern priming of mucosal immune responses have contributed to a more optimistic view on the future of mucosal vaccines. Compared to live attenuated vaccines, subcomponent vaccines, most often protein-based, are considered safer, more stable, and less complicated to manufacture, but they require the addition of nontoxic and clinically safe adjuvants to be effective. In addition, another limiting factor is the large antigen dose that usually is required for mucosal vaccines. Therefore, the combination of mucosal adjuvants with the recent progress in nanoparticle technology provides an attractive solution to these problems. In particular, the liposome technology is ideal for combining protein antigen and adjuvant into an effective mucosal vaccine. Here, we describe and discuss recent progress in nanoparticle formulations using various types of liposomes that convey strong promise for the successful development of the next generation of mucosal vaccines.

show abstract

Section: Mucosal Immune Responses To Liposomesmentioning

confidence: 99%

Mucosal Vaccine Development Based on Liposome Technology

Bernasconi

Norling

Bally

et al. 2016

Journal of Immunology Research

View full text Add to dashboard Cite

show abstract

“…The electrostatic and hydrogen interactions among the excipients thus provide biohybrid systems with improved properties, such as the delivery profile of active molecules increasing plasma halflife [83], permeation [84], and efficacy [85]. Furthermore, this combination of materials can be used to modulate viscosity, consistency, and mucoadhesion of lipid nanoparticles [86] or to add thermoreversible properties to the systems [87,88].…”

Section: Innovative Hybrid Lipid Nanoparticles: Solid Lipid Nanopartimentioning

confidence: 99%

“…Rose et al [87] developed optimized lipid-polymer nanoparticles composed of PLGA electrostatically modified with dimethyl octadecyl ammonium as cationic surfactant and conjugated with a complex formed between the glycolipid trehalose dibehenate and PVA. This formulation aimed to act as an immunopotentiator to modify cellular and humoral immunity by antibodies and Th1/Th17 responses, proposed as adjuvant in topical vaccine, improving the specificity of the system against many bacterial pathogens of the oral mucosa.…”

Section: Innovative Hybrid Lipid Nanoparticles: Solid Lipid Nanopartimentioning

confidence: 99%

Advances in Hybrid Polymer-Based Materials for Sustained Drug Release

Ribeiro

Alcántara

Silva

et al. 2017

International Journal of Polymer Science

View full text Add to dashboard Cite

The use of biomaterials composed of organic pristine components has been successfully described in several purposes, such as tissue engineering and drug delivery. Drug delivery systems (DDS) have shown several advantages over traditional drug therapy, such as greater therapeutic efficacy, prolonged delivery profile, and reduced drug toxicity, as evidenced by in vitro and in vivo studies as well as clinical trials. Despite that, there is no perfect delivery carrier, and issues such as undesirable viscosity and physicochemical stability or inability to efficiently encapsulate hydrophilic/hydrophobic molecules still persist, limiting DDS applications. To overcome that, biohybrid systems, originating from the synergistic assembly of polymers and other organic materials such as proteins and lipids, have recently been described, yielding molecularly planned biohybrid systems that are able to optimize structures to easily interact with the targets. This work revised the biohybrid DDS clarifying their advantages, limitations, and future perspectives in an attempt to contribute to further research of innovative and safe biohybrid polymer-based system as biomaterials for the sustained release of active molecules.

show abstract

“…DoE provides the largest amount of information from the least number of experimental runs by systematic variation of the factors and simultaneous evaluation of the effects of multiple variables. Quality assurance has changed from the need to show that the final product meets predefined specifications to a new situation where it needs to be demonstrated that the product is controlled within a well-defined design space (10,11). The design space is defined as an established multidimensional range of input variables (e.g., formulation factors) and process parameters demonstrated to provide assurance of quality (12).…”

mentioning

confidence: 99%

Formulation and pharmaceutical development of quetiapine fumarate sustained release matrix tablets using a QbD approach

et al. 2017

View full text Add to dashboard Cite

The main objective of the present study was to apply QbD methodology in the development of once-a-day sustained release quetiapine tablets. The quality target product profile (QTPP) was defined after the pharmaceutical properties and kinetic release of the innovator product, Seroquel XR 200 mg. For the D-optimal experimental design, the level and ratio of matrix forming agents and the type of extragranular diluent were chosen as independent inputs, which represented critical formulation factors. The critical quality attributes (CQAs) studied were the cumulative percentages of quetiapine released after certain time intervals. After the analysis of the experimental design, optimal formulas and the design space were defined. Optimal formulas demonstrated zero-order release kinetics and a dissolution profile similar to the innovator product, with f 2 values of 74.53 and 83.74. It was concluded that the QbD approach allowed fast development of sustained release tablets with similar dissolution behavior as the innovator product.Keywords: quality by design, design of experiments, sustained release, hydrophilic matrix, quetiapineIn the past years, the main goal of antipsychotic drug development has been to develop molecules with higher efficacy and fewer side effects usually associated with the classic antipsychotic medications. The newly developed agents, called atypical antipsychotics, are successfully used in the treatment of both positive and negative symptoms of schizophrenia and are associated with fewer neurological and endocrine side effects compared to older medications (1). Quetiapine is a recently introduced atypical antipsychotic, which has an excellent risk/benefit ratio and is indicated as the first-line option for the treatment of psychotic disorder manifestations and schizophrenia (2). Quetiapine is available as fumarate salt in immediate as well as in sustained released formulations, the innovative product being Seroquel. The sustained release formulation was introduced several years ago and its primary objective is to release the drug slowly over an extended ALEXANDRU GAVAN

show abstract

Engineering of a novel adjuvant based on lipid-polymer hybrid nanoparticles: A quality-by-design approach

Cited by 85 publications

References 44 publications

Mucosal Vaccine Development Based on Liposome Technology

Mucosal Vaccine Development Based on Liposome Technology

Advances in Hybrid Polymer-Based Materials for Sustained Drug Release

Formulation and pharmaceutical development of quetiapine fumarate sustained release matrix tablets using a QbD approach

Contact Info

Product

Resources

About